Troponin‐guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor–related myocarditis

The Journal of DermatologyEarly View LETTER TO THE EDITOR Troponin-guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor–related myocarditis Rino Toyoshima, Corresponding Author Rino Toyoshima [email protected] orcid.org/0009-0006-2029-1492 Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Correspondence Rino Toyoshima, Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-0063, 3-8-31 Ariake, Koto-ku, Tokyo, Japan. Email: [email protected]Search for more papers by this authorJiro Uehara, Jiro Uehara Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorYurie Matsuzaki, Yurie Matsuzaki Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorArisa Yoshimura, Arisa Yoshimura Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorShigehisa Kitano, Shigehisa Kitano Advanced Medical Development Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorKoji Yoshino, Koji Yoshino Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this author Rino Toyoshima, Corresponding Author Rino Toyoshima [email protected] orcid.org/0009-0006-2029-1492 Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Correspondence Rino Toyoshima, Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-0063, 3-8-31 Ariake, Koto-ku, Tokyo, Japan. Email: [email protected]Search for more papers by this authorJiro Uehara, Jiro Uehara Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorYurie Matsuzaki, Yurie Matsuzaki Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorArisa Yoshimura, Arisa Yoshimura Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorShigehisa Kitano, Shigehisa Kitano Advanced Medical Development Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this authorKoji Yoshino, Koji Yoshino Department of Dermatologic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanSearch for more papers by this author First published: 12 January 2024 https://doi.org/10.1111/1346-8138.17113Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018; 4: 1721–1728. 10.1001/jamaoncol.2018.3923 PubMedWeb of Science®Google Scholar 2Lyon AR, López-Fernánde T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA). The European Society for Therapeutic Radiology and Oncology (ESTRO) and the international Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43: 4229–4361. 10.1093/eurheartj/ehac244 PubMedWeb of Science®Google Scholar 3Rossi VA, Gawinecka J, Dimitriou F, von Eckardstein A, Dummer R, Ruschitzka F, et al. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge? ESC Heart Fail. 2023; 10: 2680–2685. 10.1002/ehf2.14360 PubMedWeb of Science®Google Scholar 4Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020; 9:e013757. 10.1161/JAHA.119.013757 PubMedWeb of Science®Google Scholar 5Hu Y, Liu C, Jin S, Yi Z, Wang C, Pan X, et al. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. BMC Pulm Med. 2023; 23: 119. 10.1186/s12890-023-02417-4 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation